Sector
PharmaceuticalsOpen
₹374.3Prev. Close
₹372.45Turnover(Lac.)
₹148.29Day's High
₹377.85Day's Low
₹355.5552 Week's High
₹43052 Week's Low
₹222Book Value
₹380.45Face Value
₹10Mkt Cap (₹ Cr.)
494.58P/E
16.32EPS
22.82Divi. Yield
010 Jul 2024
12:00 AM
Board Meeting
Agenda : Audited Result
14 Jul 2023
12:00 AM
BookCloser
15 Jul 2023
12:00 AM
AGM
Announcement Date: 15 Jul, 2023
| Y/e 31 Mar( In .Cr) | Mar-2023 | Mar-2022 | Mar-2021 | Mar-2020 |
|---|---|---|---|---|
Equity Capital | 13.37 | 13.37 | 26.09 | 12.34 |
Preference Capital | 0 | 0 | 0 | 0 |
Reserves | 464.68 | 436.05 | 374.09 | 319.91 |
Net Worth | 478.05 | 449.42 | 400.18 | 332.25 |
Minority Interest |
| Y/e 31 Mar( In .Cr) | Mar-2022 | Mar-2021 | Mar-2020 | Mar-2018 |
|---|---|---|---|---|
Revenue | 575.18 | 514.62 | 322.35 | 355.07 |
yoy growth (%) | 11.76 | 59.64 | -9.21 | -5.42 |
Raw materials | -375.96 | -336.68 | -176.8 | -205.42 |
As % of sales | 65.36 | 65.42 | 54.84 | 57.85 |
Employee costs | -43.74 | -35.88 | -33.78 | -27.82 |
| Y/e 31 Mar( In .Cr) | Mar-2022 | Mar-2021 | Mar-2020 | Mar-2018 |
|---|---|---|---|---|
Profit before tax | 44.67 | 17.61 | 2.54 | -23.42 |
Depreciation | -32.57 | -34.28 | -31.05 | -32.72 |
Tax paid | 4.31 | 13.21 | -1.96 | -3.16 |
Working capital | 55.88 | -86.12 | 20.69 | -11.18 |
Other operating items |
| Y/e 31 Mar | Mar-2022 | Mar-2021 | Mar-2020 | Mar-2018 |
|---|---|---|---|---|
Growth matrix (%) | ||||
Revenue growth | 11.76 | 59.64 | -9.21 | -5.42 |
Op profit growth | 46.85 | 8.81 | -1.13 | -7.88 |
EBIT growth | 47.2 | 94.58 | 34.96 | 31.88 |
Net profit growth | -9.73 | -759.69 | -69.05 | 31.32 |
| Particulars (Rupees in Crores.) | Mar-2024 | Mar-2023 | Mar-2022 | Mar-2021 | Mar-2020 |
|---|---|---|---|---|---|
Gross Sales | 601.45 | 555.51 | 600.18 | 548.12 | 341.46 |
Excise Duty | 0 | 0 | 0 | 0 | 0 |
Net Sales | 601.45 | 555.51 | 600.18 | 548.12 | 341.46 |
Other Operating Income | 0 | 0 | 0 | 0 | 0 |
Other Income | 11.58 | 10.32 | 8.31 | 43.07 | 5.31 |
Company Name | LTP (₹) | P/E (%) | Mkt.Cap (₹Cr.) | NP Qtr (₹Cr.) | Div.Yield (%) | Sales Qtr (₹.Cr) | Book Value (₹) |
|---|---|---|---|---|---|---|---|
Sun Pharmaceuticals Industries Ltd SUNPHARMA | 1,587.35 | 124.83 | 3,80,990.4 | 867.6 | 0.85 | 5,536.99 | 98.75 |
Divis Laboratories Ltd DIVISLAB | 4,534.8 | 76.42 | 1,20,383.36 | 531 | 0.66 | 2,259 | 507.93 |
Cipla Ltd CIPLA | 1,490 | 32.38 | 1,20,295.96 | 1,038.4 | 0.57 | 3,444.92 | 346.41 |
Zydus Lifesciences Ltd ZYDUSLIFE | 1,154.55 | 33.79 | 1,16,159.65 | 1,405.2 | 0.26 | 3,172.6 | 156.19 |
Dr Reddys Laboratories Ltd DRREDDY | 6,770.9 | 26.36 | 1,12,931.2 | 1,034.8 | 0.59 | 5,081.8 | 1,458.96 |
Figures of Market Capital(Mar Cap), Quarterly Net Profit(NP Qtr) and Quarterly Sales(Sales Qtr) are in ₹ Cr.
Chairman & Managing Director
Pawan Chaudhary
Joint Managing Director
Manu Chaudhary
Deputy Managing Director
Peeyush Jain
Executive Director
Ashutosh Jain
Independent Director
Gilbert Wenzel
Independent Director
S. K. Chadha
Company Sec. & Compli. Officer
Neha Kodan
Independent Director
Navdeep Sud
Independent Director
Savita Gupta
Whole-time Director
Akshansh Chaudhary
Independent Director
Nps Monga
Tel: -
Website: -
Email: -
Tel: -
Website: -
Email: -
Reports by Venus Remedies Ltd
Summary
Incorporated in 1989 Venus Remedies Ltd (formerly known Venus Glucose Pvt Ltd), was converted into Public Limited Company in 1994 and then changed into Venus Remedies Limited. The Company was promoted and managed by Chaudhary & Family. The Company is one of the handful player in pharmaceutical sector to launch injectables globally. It has manufacturing facilities in Panchkula and Baddi , and research and development centre under the name of Venus Medicine Research Centre (in India). In priority, the Company was mainly engaged in I/V Fluids & Injectables, Ceftazidime, Amlodipine, Gliclazide, Lisinopril, etc.The production was started in 1991 with Intravenous/Intramuscular injectible forms at Panchkula district at Haryana. In 1994 it introduced Eye/Ear/Nose drops. The company received the certificate as WHO-GMP as specified by WHO,Geneva. Venus Remedies set up a Cephalosporin project with an Australian collaboration with US-FDA standards at a cost of Rs.4.5 crores. The company is manufacturing injections for the top companies like Panacea Biotech ltd,Morepan Labortories ltd etc.In 2001 with the help of Product Development Committee(PDC) Venus Remedies had introduced 13 new products in the Animal Health Division namely Megox-3000,Paroxin-3000,Pisa-3000,Mical,Ronid,Dexolyte and Detox.The year 2005-06 saw many new milestone achievements by the Company like commercial operation of its most modern and techno-savvy manufacturing unit at Baddi, formation of a WOS in Germany and acquis
Read More
What is the Venus Remedies Ltd share price today?
The Venus Remedies Ltd shares price on N/A is Rs.₹367.1 today.
What is the Market Cap of Venus Remedies Ltd?
Market capitalization, short for market cap, is the market value of a publicly traded company's outstanding shares. The market cap of Venus Remedies Ltd is ₹490.70 Cr. as of 23 Jul ‘24
What is the PE and PB ratio of Venus Remedies Ltd?
The PE and PB ratios of Venus Remedies Ltd is 16.32 and 0.98 as of 23 Jul ‘24
What is the 52 Week High and Low of Venus Remedies Ltd?
The 52-week high/low is the highest and lowest price at which a Venus Remedies Ltd stock has traded during that given time period (similar to 1 year) and is considered as a technical indicator. The 52 week high and low of Venus Remedies Ltd is ₹222 and ₹429.6 as of 23 Jul ‘24
What is the CAGR of Venus Remedies Ltd?
Venus Remedies Ltd's CAGR for 5 Years at 78.07%, 3 Years at -7.30%, 1 Year at 35.07%, 6 Month at -1.12%, 3 Month at 11.58% and 1 Month at -2.53%.
What is the shareholding pattern of Venus Remedies Ltd?
The shareholding pattern of Venus Remedies Ltd is as follows:
Promoters - 41.76 %
Institutions - 1.21 %
Public - 57.03 %
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Securities Support WhatsApp Number
+91 9892691696
Download The App Now
Follow us on
2024, IIFL Securities Ltd. All Rights Reserved
www.indiainfoline.com is part of the IIFL Group, a leading financial services player and a diversified NBFC. The site provides comprehensive and real time information on Indian corporates, sectors, financial markets and economy. On the site we feature industry and political leaders, entrepreneurs, and trend setters. The research, personal finance and market tutorial sections are widely followed by students, academia, corporates and investors among others.
Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.
